Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 23;51(1):afab242. doi: 10.1093/ageing/afab242

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Geriatrics Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Secondary mobility endpoints. Panel A: Left column: therapeutic areas ordered by number of studies. Adjacent column: total numbers of mobility endpoints and their subtypes. The sizes of the circles are proportional to the total numbers. Top: column chart: number of different mobility assessments performed by therapeutic area; names of mobility tests are printed above the column if their number does not exceed three; therapeutic areas with more than three different mobility assessements are marked with an asterisk (*). Tests used in multiple therapeutic areas are connected by lines. The therapeutic area corresponding to the column is identified by a grey dot in the network plot below. Panel B: therapeutic areas with more than three different mobility tests. Pie charts show the total number of secondary mobility endpoints employed in the studies of the five therapeutic areas. ‘Other’ denotes secondary mobility endpoints ocurring in less than 5% of all secondary mobility endpoints within each therapeutic area. ACR, American College of Rheumatology; ASAS, Assessment in Ankylosing Spondylitis; BASFI, Bath Ankylosing Spondilitis Functional Index; CAT, COPD Assessment Test; E-RS, Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease; SOBDA, Shortness of Breath with Daily Activities questionnaire; MSIS, Multiple Sclerosis Impact Scale; MSFC, Multiple Sclerosis Functional Composite; UPDRS, Unified Parkinson’s Disease Rating Scale; mod.H&Y, modified Hoehn and Yahr; PDQ, Parkinson’s Disease Questionnaire; MLHFQ-PH, Minnesota Living With Heart Failure Questionnaire; 6-MWT, Six Minute Walk Test; MAF, Multi-dimensional Assessment of Fatigue; WLQ, Work Limitations Questionnaire; AQLQ, Asthma quality of Life Questionnaire; ECOG, Eastern Co-operative of Oncology Group Performance Score; EORT, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core; NEI-VFQ, National Eye Institute 25-item Visual Function Questionnaire; FIQ, Fibromyalgia Impact Questionnaire Physical Functioning; WLQ, Work Limitations Questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire—Clinical Summary Score; BPI, Brief Pain Inventory; SGRQ, St. George’s Respiratory Questionnaire; HAQ-DI, Health Assessment Questionnaire—Disability Index; NYHA, New York Heart Association Functional Class; SF-36(PF), Short Form 36 Physical Functioning Subscale; SF-36(PCS), Short Form 36 Physical Component Summary; EQ-5D, EuroQol 5 Dimensions.